The pharmaceutical industry has an issue that has been ongoing for years. The price of drugs are outrageous. Drug prices are unregulated and a lot of Americans are unaware of what pharmaceuticals do. They control the pricing of drugs that are prescribed to patients. In recent articles written by Andrew Pollack from The New York Times and Heather Long from CNN Wire, they discuss a similar topic but provide their information gathered from different perspectives. One takes the issue on whether it is lawful and just, while the other just gives basic information on the situation.
While both news articles discuss the shocking price increase of the drug, Daraprim. The CNN Wire article, "Drug That Skyrocketed 5,000% Hasn 't Come down in Price," by Heather Long, provides a more elaborate reasoning of why it was increased. She quotes Martin Shkreli, the CEO for Turing Phamaceuticals, in how he wants to “develop a new drug for toxoplasmosis.” She also mention him saying that he has agreed to lower the price of the drug. He made the announcement in September that he would lower the price of Daraprim, which caused people to brush it off. Since, no new …show more content…
As stated before, generic drug makers cannot test the drug, therefore they cannot copy the drug and sell it. He takes the money issue and focuses it on drug makers and not on the people.
The similarities of the news articles were fairly small. They compared in the way they both discussed Martin Shkreli’s drug price increase, because a high price is needed to improve Daraprim. They also were similar in how he wants to lower the price to where it is more affordable. In all honestly, that is how they compared. They explained the price hike of Daraprim, they explained what the drug does, and how Shkreli plans on bettering the drug with the profit of
While both news articles discuss the shocking price increase of the drug, Daraprim. The CNN Wire article, "Drug That Skyrocketed 5,000% Hasn 't Come down in Price," by Heather Long, provides a more elaborate reasoning of why it was increased. She quotes Martin Shkreli, the CEO for Turing Phamaceuticals, in how he wants to “develop a new drug for toxoplasmosis.” She also mention him saying that he has agreed to lower the price of the drug. He made the announcement in September that he would lower the price of Daraprim, which caused people to brush it off. Since, no new …show more content…
As stated before, generic drug makers cannot test the drug, therefore they cannot copy the drug and sell it. He takes the money issue and focuses it on drug makers and not on the people.
The similarities of the news articles were fairly small. They compared in the way they both discussed Martin Shkreli’s drug price increase, because a high price is needed to improve Daraprim. They also were similar in how he wants to lower the price to where it is more affordable. In all honestly, that is how they compared. They explained the price hike of Daraprim, they explained what the drug does, and how Shkreli plans on bettering the drug with the profit of